| abstract |
Disclosed herein are triazole derivative compounds of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use as inhibitors of the NK-1 subtype of tachykinin receptors, as well as a process for their preparation and intermediates therefor, wherein: D is a C1-C3 alkane-diyl; R1 is phenyl, which is optionally substituted with one to three substituents independently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; R4 is a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH); and R5 is hydrogen, halo, trifluoromethyl, C1-C4 alkyl, C3-C6 cycloalkyl, furyl, thienyl, pyrrolyl, imidazolyl, -NR16R17, pyridyloxy, phenyl, phenoxy, phenylthio, anilino, which phenyl, phenoxy, phenylthio, or anilino group may be optionally substituted on the phenyl ring with one or two substituents independently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, -S(O)q(C1-C4 alkyl), or as defined in the specification, and wherein the other variables as shown in these formulae are as defined in the specification. These triazole derivatives are suitable for the treatment of anxiety, depression, irritable bowel syndrome, or emesis. |